Rajiv Parikh, MD
Family Medicine · Tempe, AZNPI 1811961774
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,608 of the $14,844 with a category attached, or 84.9%. 60 manufacturers reported payments, led by Novo Nordisk at 24.6% of the total. Among family medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 723 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Amgen$964
- Lilly USA, LLC$842
- AbbVie$662
- plus $5K from 54 others
Across 79 payments — averaging $11,817 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$347K
- AstraZeneca$346K
- GSK$127K
- Chiesi USA, Inc.$45K
- Eli Lilly$43K
- Sanofi US Services Inc.$25K
- plus $1K from 1 others
What the payments were for
- Consulting fees$2,13014%
- Food & beverage$12,60885%
- Education$1051%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,844 in reported general payments places this provider in the 95th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $120,953 |
| JardianceEmpagliflozin | 70 | $88,164 |
| TrulicityDulaglutide | 50 | $84,050 |
| EliquisApixaban | 53 | $72,514 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $62,131 |
| MounjaroTirzepatide | 42 | $57,844 |
| XareltoRivaroxaban | 54 | $57,219 |
| FarxigaDapagliflozin Propanediol | 49 | $42,163 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 11 | $39,427 |
| JanumetSitagliptin Phos/Metformin Hcl | 26 | $35,567 |
| ProliaDenosumab | 19 | $33,011 |
| GemtesaVibegron | 30 | $31,962 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $23,137 |
| LinzessLinaclotide | 23 | $18,215 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $17,867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $842 | $141,89492 claims |
| Novo NordiskOzempic | $3,647 | $120,95363 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat | $1,378 | $117,655101 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,965 | $75,63894 claims |
| PfizerEliquis | $423 | $72,51453 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $452 | $69,08558 claims |
| Johnson & JohnsonXarelto | $315 | $57,21954 claims |
| MerckJanumet, Januvia, Belsomra | $136 | $55,16053 claims |
| AmgenProlia | $964 | $33,01119 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $47 | $31,96230 claims |
| AbbVieLinzess | $662 | $18,21523 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $80 | $17,86711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Tempe
- Simon SheardTempe$27K
- Alan AndresenTempe$22K
- Curtis PageTempe$16K
- Anne Marie ReedTempe$13K
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Lorena Jauregui-CovarrubiasYuma$491K
- Sam FereidouniScottsdale$486K
- Jessica BlancoChandler$447K
- Heather ElwoodPhoenix$236K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.